Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim N Chi

Showing results (31-40 of 234) with videos related to

Pageof 24
Sort By:
Cancer|December 7, 2018
Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: Results from LATITUDETracy Li, Conrado Franco-Villalobos, Irina Proskorovsky, et al.
American Journal of Clinical Oncology|October 24, 2002
Carboplatin and vinblastine for the treatment of metastatic transitional cell carcinoma of the urothelial tractHuda A Al-Karim, Kennard E Tan, Kim N Chi, et al.
European Urology|June 30, 2009
Castration-resistant prostate cancer: from new pathophysiology to new treatment targetsKim N Chi, Anders Bjartell, David Dearnaley, et al.
International Journal of Molecular Sciences|April 12, 2013
Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancerAkira Watahiki, Robyn J Macfarlane, Martin E Gleave, et al.
Oncotarget|November 28, 2014
PD-L1 is highly expressed in Enzalutamide resistant prostate cancerJennifer L Bishop, Alexander Sio, Arkhjamil Angeles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgeryChristian Kollmannsberger, Siamak Daneshmand, Alan So, et al.
Plos One|January 14, 2014
Morphological differences between circulating tumor cells from prostate cancer patients and cultured prostate cancer cellsSunyoung Park, Richard R Ang, Simon P Duffy, et al.
Investigational New Drugs|July 14, 2005
A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancerKim N Chi, Stephen K Chia, Ross Dixon, et al.
Journal of the National Cancer Institute|September 8, 2005
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancerKim N Chi, Elizabeth Eisenhauer, Ladan Fazli, et al.
International Journal of Cancer|January 21, 2014
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, CanadaReka Pataky, Roman Gulati, Ruth Etzioni, et al.
Pageof 24

Showing results (31-40 of 234) with videos related to

Sort By:
Pageof 24
Cancer|December 7, 2018
Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: Results from LATITUDETracy Li, Conrado Franco-Villalobos, Irina Proskorovsky, et al.
American Journal of Clinical Oncology|October 24, 2002
Carboplatin and vinblastine for the treatment of metastatic transitional cell carcinoma of the urothelial tractHuda A Al-Karim, Kennard E Tan, Kim N Chi, et al.
European Urology|June 30, 2009
Castration-resistant prostate cancer: from new pathophysiology to new treatment targetsKim N Chi, Anders Bjartell, David Dearnaley, et al.
International Journal of Molecular Sciences|April 12, 2013
Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancerAkira Watahiki, Robyn J Macfarlane, Martin E Gleave, et al.
Oncotarget|November 28, 2014
PD-L1 is highly expressed in Enzalutamide resistant prostate cancerJennifer L Bishop, Alexander Sio, Arkhjamil Angeles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgeryChristian Kollmannsberger, Siamak Daneshmand, Alan So, et al.
Plos One|January 14, 2014
Morphological differences between circulating tumor cells from prostate cancer patients and cultured prostate cancer cellsSunyoung Park, Richard R Ang, Simon P Duffy, et al.
Investigational New Drugs|July 14, 2005
A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancerKim N Chi, Stephen K Chia, Ross Dixon, et al.
Journal of the National Cancer Institute|September 8, 2005
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancerKim N Chi, Elizabeth Eisenhauer, Ladan Fazli, et al.
International Journal of Cancer|January 21, 2014
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, CanadaReka Pataky, Roman Gulati, Ruth Etzioni, et al.
Pageof 24